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Abstract
Ectopic programmed cell death ligand 1 (PD-L1) expression in non-small cell lung cancers
(NSCLCs) is related to immune evasion by cancer, and it is a molecular target of immune
checkpoint therapies. Although some altered signals in NSCLCs are responsible for ectopic
PD-L1 expression, the precise mechanisms remain obscure. Because we found a higher
frequency of EGFR/KRAS mutations in NSCLC cell lines with high PD-L1 expression (p <
0.001), we evaluated the relationships between downstream signals and PD-L1 expression,
particularly in three KRAS-mutant adenocarcinoma cell lines. The MEK inhibitor U0126
(20 μM) significantly decreased the surface PD-L1 levels by 50–60% compared with
dimethyl sulfoxide (p < 0.0001). Phorbol 12-myristate 13-acetate stimulation (100 nM, 15
min) increased (p < 0.05) and two ERK2 siRNAs as well as KRAS siRNAs decreased (p <
0.05) PD-L1 expression. The transcriptional activity of the potential AP-1 site (+4785 to
+5056 from the transcription start site) in the PD-L1 gene was demonstrated by luciferase
assays, which was inhibited by U0126. The chromatin immunoprecipitation assay demon-
strated the binding of cJUN to the AP-1 site. Two STAT3 siRNAs decreased PD-L1 expres-
sion by 10–32% in two of the three KRAS-mutant lung adenocarcinoma cell lines (p < 0.05),
while the PI3K inhibitor LY294002 (40 μM) did not change the expression level. Supervised
cluster analysis and gene set enrichment analysis between the PD-L1-high and -low
NSCLCs revealed a correlation between PD-L1 expression and genes/pathways related to
cell motility/adhesion. These results indicate that MAPK signaling is the dominant down-
stream signal responsible for ectopic PD-L1 expression, in which STAT3 is also involved to
some extent. Furthermore, MAPK signaling may control the expression of PD-L1 and sev-
eral genes related to enhanced cell motility. Our findings suggest that MAPK, along with
STAT3, is important for determining PD-L1 expression, which could be useful for targeted
therapies against lung cancers.
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Introduction
Recent advances in immune checkpoint therapies are rapidly changing the clinical applications
of cancer therapies [1]. Programmed cell death ligand 1 (PD-L1), also known as cluster of dif-
ferentiation 274 (CD274) and B7 homolog 1 (B7-H1), is widely expressed in normal tissues
(natural killer cells, T and B cells, macrophages, dendritic cells, epithelial cells, and vascular
endothelial cells). It is a ligand for programmed cell death 1 (PD-1) receptors expressed on
activated T cells [2]. PD-L1/PD-1 interaction is an important immune checkpoint that restricts
excessive adaptive immune responses, maintaining immune homeostasis [2]. However, in
chronic viral infection or cancers, the continuous exposure of antigen-primed T cells to anti-
gens induces PD-1 on their surfaces. The PD-L1/PD-1 interaction inhibits signals from the T-
cell receptor, leading to T cells that are exhausted, a state characterized by being unresponsive
to antigens [3].
Ectopic PD-L1 expression has been reported in many different tumor types including lung
cancer [4], and it is considered to be one of the mechanisms of immune evasion. Clinical trials
have demonstrated the clinical activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies for
various tumors including non-small cell lung cancers (NSCLCs), with a response rate of 10%
to 30% [5]. Although the significance of PD-L1 expression as a biomarker in cancers is contro-
versial, it should be considered in the context of an immune evasion network created by cancer
cells. An immunosuppressive microenvironment is a complex and dynamic state involving
various molecules and cells, which originates from constitutively altered signals within cancer
cells. These signals also regulate proliferation or metastasis and constitute oncogenic signals as
evidenced in STAT3 [6] or mutated BRAF (V600E) [7]. Several driver oncogene products can
be molecular targets for cancer immunotherapy and are now under vigorous investigation [8].
The mechanisms of ectopic PD-L1 expression have been examined in various cancers [9–
19]. However, the signal pathways responsible for its expression have been found to differ
among various cancers. For NSCLCs, EGFR mutation [10,11], EML4-ALK rearrangement
[13], or microRNAs [12] have been reported to regulate PD-L1 expression. The MAPK sig-
nal against a background with these mutations has been reported to contribute to PD-L1
expression [13], but the precise mechanism involved in this has not yet been demonstrated.
Here we examined the signaling pathways that regulate PD-L1 expression in KRAS-mutant
NSCLCs and demonstrated that MAPK signaling and downstream AP-1 are crucial for
PD-L1 expression.
Materials and Methods
Cell lines
NCI-H522, NCI-H1373, NCI-H1650, NCI-H1975, NCI-H23, NCI-H358, NCI-H441,
NCI-H647, SK-LU-1, NCI-H226, NCI-H2170, SKMES-1, DMS114, NCI-H460, and BEAS-2B
were purchased from American Type Culture Collection. ABC-1, RERF-LC-MS, VMRC-LCD,
EBC-1, LK-2, and SBC-5 were purchased from the Japanese Collection of Research Biore-
sources Cell Bank. All cell lines except NCI-H647, which was studied immediately after pur-
chase, were authenticated by short tandem repeat DNA typing before submission.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
mRNA expression in the cell lines was quantified by real-time PCR using the TaqMan PCR
assay for PD-L1 (CD274) or SYBR Green Gene Expression Assays (Applied Biosystems) for
KRAS, ERK2, STAT3, RAC2, CDA, ANXA3,MST1R, VAV1, FBXL13, SH3KBP1, TRIP6, TGFβ1,
TNFAIP8, or RAET1E and was analyzed by a relative quantitative method (ΔΔCt method) for
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the target mRNA, which was normalized by control β-actin mRNA and BEAS-2B as a refer-
ence control cell.
Mutational analysis of driver oncogenes
Information on the mutational status of driver oncogenes in the cell lines was obtained from
the Cancer Cell Line Encyclopedia (CCLE) provided by the Broad Institute and Novartis Insti-
tutes for Biomedical Research (http://www.broadinstitute.org/ccle/home), as well as from Cat-
alogue of somatic mutations in cancer (COSMIC) (http://cancer.sanger.ac.uk/cosmic).
Flow cytometric analysis
Cells were stained with fluorescein isothiocyanate (FITC)-conjugated mAb specific for PD-L1
(MIH1) or the isotype control IgG (MOPC-21) and propidium iodide (PI) (BD Pharmingen).
Cell acquisition and analysis were performed with FACSCalibur and CELLQuestPro software
(Becton Dickinson). The relative mean fluorescence intensity (MFI) was calculated using the
following equation: PD-L1 MFI/isotype control MFI in the PI-negative fraction.
Inhibitor and RNA interference (RNAi) experiments
For in vitro inhibitor assays, U0126 or LY294002 (Cell Signaling Technology; CST) dissolved
in dimethyl sulfoxide (DMSO) (Wako) was added to the cells at a final concentration of 20 or
40 μM, respectively, as well as to the same amount of DMSO as a control, and incubated for 24
h. For RNAi experiments, cells plated at 50–60% confluence in a 6-cm dish were transfected
with siRNAs specific for ERK2 mRNA (#1, 50-GACACAACACCUCAGCAAU-30 and #2, 50-
CUAACGUUCUGCACCGUGA-30), KRAS mRNA (#1, 50-CUCAGGACUUAGCAAGAAGUU-30
and #2, 50-CAGUUGAGACCUUCUAAUUGG-30), or STAT3 mRNA (#1, 50-GCCUCAAGAUUGA
CCUAGA-30 and #4, 50-AUAGGAAGGUUUAAGGAGA-30) as well as a control siRNA (siCtrl)
(directed against firefly luciferase mRNA) (50-GUGCGCUGCUGGUGCCAAC-30) (all obtained
from Sigma) at 100 nM with Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfec-
tion, cells were harvested for flow cytometry, immunoblot, and qRT-PCR assays.
Immunoblot analysis
Cells were lysed in RIPA buffer containing Halt Protease and Phosphatase Inhibitor Cocktail
(Thermo Scientific). Proteins were separated on 10.0% SDS-polyacrylamide gels. The follow-
ing primary mAbs were used: phospho-p44/42 MAPK (Thr202/Tyr204) (D13.14.4E, rabbit
monoclonal; CST), ERK2 (C14, rabbit polyclonal; Santa Cruz), phospho-AKT (Ser473) (D9E,
rabbit monoclonal; CST), AKT (C67E7, rabbit monoclonal; CST), phosphor-STAT3 (rabbit
polyclonal, #931; CST), STAT3 (124H6, mouse monoclonal; CST), KRAS (234–4.2, mouse
monoclonal; Calbiochem), PD-L1 (E1L3N, rabbit monoclonal; CST), β-actin (8H10D10,
mouse monoclonal; CST), and GAPDH (14C10, rabbit monoclonal; CST). Horseradish perox-
idase-conjugated goat Ab to rabbit IgG (NA931) or donkey Ab to mouse IgG (NA934) (GE
Healthcare) was used as the secondary Ab. Immune complexes were detected with ECL Prime
Western Blotting Detecting Reagent (GE Healthcare) and ImageQuant LAS 4000 min (GE
Healthcare).
Phorbol 12-myristate 13-acetate (PMA) stimulation analysis
Cells were conditioned with DMSO or U0126 (20μM) for 1hr, 48 h after serum deprivation,
followed by stimulation with 100 nM PMA (Sigma). Fifteen minutes later, cells were harvested
for immunoblot and qRT-PCR assays.
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Construction of luciferase gene plasmids
The candidate promoter region [−2403 to +153, relative to the transcription start site (TSS),
which was determined by DBTSS (http://dbtss.hgc.jp/)] was amplified from genomic DNA
purified from NCI-H1373 cells by PCR with PrimeSTAR GXL DNA Polymerase (Takara) and
the following primer set: forward primer, 50-ACCTGAGCTCGCTAGCAACATGACTCACCTGAG
GACAA-30; and reverse primer, 50-TATCCTCGAGGCTAGCTCCATCCCAAAGAAAGGGTGTA
G-30. The PCR product was subcloned upstream of the luciferase gene of pGL4.17 basic lucif-
erase plasmid (Promega) with the In-Fusion HD Cloning Kit (Takara) (PDL-P).
The region within the first intron of PD-L1 was assessed for the candidate enhancer element
of AP-1 binding sites using publicly available chromatin immunoprecipitation (ChIP)-seq
data from the UCSC Genomic Browser (http://genome.ucsc.edu). One candidate region con-
taining an AP-1 binding site (+4785 to +5056 relative to TSS) was amplified by PCR with the
following primer set: forward primer, 50-ttGGATCCAGCACAGAAGAGGTGCTCAA-30 and
reverse primer, 50-ttGGATCCCTTCAGGTGCCATCCTTCAA-30 (the underlines at the 50-ends
show the BamHI site for subcloning). The PCR product was cloned to the BamHI site down-
stream of the luciferase gene of PDL-P (PDL-P+E). The cloned DNA fragments were con-
firmed by sequencing before the assays.
Luciferase assay
NCI-H1373 cells were dispensed to Nunclon Delta Surface, a 96-well white-bottomed plate
(Thermo Scientific, 136101) the day before transfection. Upon transfection, the cell density
reached approximately 50%. One hundred nanograms of firefly luciferase plasmid (pGL4.17
basic, PDL-P, or PDL-P+E) and 100 ng of pGL4.74 [hRluc/TK] plasmid (Promega), which
encodes Renilla luciferase driven by a thymidine kinase promoter, were co-transfected with
FuGENE6 (Promega) at a FuGENE (μL) to DNA (μg) ratio of 6. Two hours later, DMSO or
U0126 (20 μM) was added. Twenty-four hours after the transfection, the firefly and Renilla
luciferase activities were determined with the Dual-Glo Luciferase Assay System (Promega)
and an infinite M200 (TECAN) multiplate reader. After subtracting the background activity,
each firefly luciferase activity was normalized using Renilla luciferase activity to determine the
transfection efficiency.
ChIP assay
ChIP was conducted for cJun in NCI-H1373 cells. Immunoprecipitation of the predicted AP-
1-responsive element was conducted using the ChIP-IT Express Enzymatic Kit (Active Motif)
and cJun mAb (60A8, rabbit monoclonal IgG; CST) or isotype control mAb (DA1E, rabbit
monoclonal IgG; CST), followed by qRT-PCR with SYBR Green Gene Expression Assays and
the following primer set: forward primer, 50-TCACATTTCAAGCAGGATGACTAAA-30 and
reverse primer, 50-TGACTCACAGCCACTCTTCCA-30. The amount of immunoprecipitated
AP-1-responsive element was determined using a standard curve constructed from the serial
dilution of input DNA, and fold enrichment was calculated using the cJun/isotype control
value.
Supervised cluster analysis and gene set enrichment analysis (GSEA)
Supervised cluster analysis and GSEA were conducted between the PD-L1-high and -low lung
cancer cell lines using CCLE Analysis Tools: Differential Expression and Gene Set Enrichment
Analysis (GSEA) (http://www.broadinstitute.org/ccle/data/browseAnalyses).
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Statistical analysis
Unpaired Student’s t test was used for comparison of the two groups. Data are expressed as
mean ± standard deviation (SD). The correlation between MFI and RQ of PD-L1 expression
was evaluated by Pearson’s correlation test. Chi-square test was used for comparing the fre-
quency of the two groups, and a p-value of less than 0.05 was regarded as significant.
Results
High correlation between PD-L1 mRNA and surface PD-L1 protein levels
in human lung cancer cell lines
We determined PD-L1 mRNA levels of a human lung cancer cell line panel as the relative
quantity (RQ) to that of BEAS-2B, a human bronchial cell line (Fig 1A) and discriminated
between the PD-L1-high and -low groups based on the PD-L1 mRNA level of BEAS-2B. We
performed flow cytometry analysis of surface PD-L1 for 20 cell lines from both PD-L1-high
(PD-L1 RQ> 2.7) and PD-L1-low (PD-L1 RQ< 1) groups (S1 Fig). MFI of PD-L1 was nor-
malized by that of the isotype control and is shown as the MFI ratio (S1 Table). The correlation
between the mRNA and the MFI ratio of PD-L1 was moderate (Pearson’s correlation coeffi-
cient, R = 0.389), indicating that transcriptional regulation is important for ectopic PD-L1
expression (Fig 1B). Although our results could not rule out the possible co-existence of a
post-transcriptional regulatory mechanism, our observation that all PD-L1-high mRNA
(R> 2.7) cell lines expressed a substantial amount of PD-L1 on their surfaces suggests that
post-transcriptional regulation is not a dominant mechanism regulating PD-L1 levels.
Higher PD-L1 expression in lung cancer cells is associated with a higher
frequency of EGFR or KRAS mutation
We obtained information about the mutational status of major driver oncogenes or a tumor
suppressor gene in the 20 human lung cancer cell lines from the CCLE. The PD-L1-high group
contained two EGFR-mutant and five KRAS-mutant cell lines, the histological characteristics
of which resulted six of them being classified as adenocarcinomas and one as a large cell carci-
noma, while the PD-L1-low group contained only two KRAS-mutant adenocarcinoma cell
lines (Table 1). Because the mutations found in other oncogenes (ALK, RET, ROS1, and
ERBB2) reside outside known functional domains or potential phosphorylation sites, the func-
tional significance of these mutations cannot be specified. The frequency of either EGFR or
KRAS mutations in the PD-L1-high group was significantly higher than that in the PD-L1-low
group (p = 0.00056). We obtained the same result about mutational status of EGFR or KRAS
by COSMIC database. We inferred that the downstream signals of EGFR or KRAS might regu-
late PD-L1 expression.
MAPK signal regulates PD-L1 expression in human lung cancer cells
Three KRAS-mutant lung adenocarcinoma cell lines (NCI-H1373, NCI-H358, and NCI-H441)
were evaluated for PD-L1 expression 24 h after treatment with the MEK inhibitor U0126. Flow
cytometry analysis revealed a 50–60% decrease of surface PD-L1 expression with U0126 com-
pared with that with DMSO (Fig 2). Time course experiments showed that PD-L1 suppression
with U0126 was similar between 24 and 48 h but weaker at 72 h (data not shown). PD-L1
mRNA levels also significantly decreased with U0126 (Fig 2B), suggesting that transcriptional
regulation under the MAPK signal is important for PD-L1 expression. Immunoblotting indi-
cated a decrease in phospho-ERK levels (Fig 2B) but no change in phospho-AKT (T308) or
phospho-STAT3 (Y705) levels (data not shown).
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Fig 1. PD-L1 mRNA levels are correlated to surface PD-L1 protein levels in human lung cancer cell lines. A, Quantitative RT-PCR results
of PD-L1 mRNA in human lung cancer cell lines (histological features: 12 adenocarcinomas, 5 squamous cells, 2 small cells, and 1 large cell) is
shown as RQ using the ΔΔCt method with BEAS-2B as a reference. Bars and error bars represent the mean and SD of the technical triplicates,
respectively. B, The correlation between the mRNA and surface expression levels of PD-L1. A positive correlation was found between the mRNA
and protein levels (Pearson’s correlation coefficient, R = 0.389).
doi:10.1371/journal.pone.0166626.g001
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To examine the possible post-transcriptional regulation of PD-L1 under an MAPK signal,
miR-200a, miR-200b, and miR-200c, which were previously described as being responsible for
the post-transcriptional suppression of PD-L1 in human lung cancers [12], were quantified in
the three KRAS-mutant lung adenocarcinoma cell lines after DMSO or U0126 treatment (S2
Fig). U0126 treatment significantly increased miR-200a expression in one (NCI-H358), miR-
200b expression in two (NCI-H358 and NCI-H441), and miR-200c expression in two
(NCI-H1373 and NCI-H358) cell lines, suggesting that the MAPK signal suppresses some
miRNAs, counteracting the post-transcriptional suppression of PD-L1 by miRNAs in some
cell lines. However, the increase in miRNA expression with U0126 was generally weak (9–
37%) and inconsistent among the cell lines. So we cannot conclude that miRNA is universally
regulated by MAPK signaling.
U0126 significantly decreased PD-L1 expression at both protein and mRNA levels in the
NCI-H1975 lung adenocarcinoma cell line with an EGFR mutation, in the EBC-1 lung squa-
mous cell carcinoma cell line without an EGFR/KRAS/ALKmutation, and in the NCI-H460
lung large cell carcinoma with a KRAS (Q61H) mutation (S3 Fig), suggesting that the MAPK
signal contributes to PD-L1 expression irrespective of any histological differences.
To support the specificity of the MAPK signal for PD-L1 regulation, we subjected the three
KRAS-mutant lung adenocarcinoma cell lines to PMA stimulation in order to directly activate
ERKs, which was associated with a significant increase in PD-L1 mRNA levels (Fig 3A).
Table 1. Mutational status of human lung cancer cell lines.
Cell line Histology EGFR KRAS ALK BRAF MET RET ROS1 ERBB2 PTEN
PD-L1 high NCI-H1373 Ad wt G12C p.E1435dela wt wt wt wt wt wt
NCI-H441 Ad wt G12V wt wt wt wt wt wt wt
NCI-H647 Ad wt G13D wt wt wt wt wt wt wt
NCI-H1650 Ad p.ELREA746del wt wt wt wt wt wt wt wt
NCI-H358 Ad wt G12C wt wt wt wt wt wt wt
NCI-H1975 Ad L858R, T790M wt wt wt wt wt wt wt wt
NCI-H226 Sq wt wt wt wt wt wt wt wt wt
SK-MES-1 Sq wt wt wt wt wt wt wt wt wt
EBC-1 Sq wt wt wt wt wt wt wt wt wt
NCI-H460 La wt Q61Hb wt wt wt wt wt wt wt
PD-L1 low SK-LU-1 Ad wt G12D wt wt wt wt wt wt wt
VMRC-LCD Ad wt wt wt wt wt wt wt wt wt
ABC-1 Ad wt wt wt wt wt wt wt wt wt
RERF-LC-MS Ad wt wt wt wt wt wt wt wt wt
NCI-H23 Ad wt G12C wt wt wt R77Lc wt wt wt
NCI-H522 Ad wt wt wt wt wt wt wt wt wt
NCI-H2170 Sq wt wt wt wt wt wt wt wt wt
LK-2 Sq wt wt wt wt wt wt wt wt wt
SBC-5 SCLC wt wt wt wt wt wt wt S1050Le wt
DMS114 SCLC wt wt wt wt wt wt T870Nd wt wt
wt: wild type
a
, E1435 resides downstream of the tyrosine kinase domain (1116–1383) of ALK; its significance is unknown.
b
, Q61H is a minor mutation in exon 3 of KRAS.
c
, R77L of RET is located at the N-terminus; its significance is unknown.
d
, T870N of ROS1 resides outside any known motifs; its significance is unknown.
e
, S1050L of ERBB2 resides near the Tyr1054 residue downstream of the tyrosine kinase domain; its significance is unknown.
doi:10.1371/journal.pone.0166626.t001
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Fig 2. MEK inhibition significantly decreased PD-L1 expression in human lung cancer cell lines. A,
Gating strategy for the determination of PD-L1 levels in lung cancer cell lines stained with FITC anti-PD-L1
mAb. For differentiation between live and dead cells, PI exclusion staining was used. B, (upper)
Representative histogram of PD-L1 (shaded histogram) of three KRAS-mutant lung adenocarcinoma cell
lines with DMSO or U0126 (20 μM) for 24 h. Empty histogram indicates the isotype control. (upper middle)
Relative MFI (PD-L1 MFI / isotype control MFI) of the three cell lines was significantly decreased with U0126.
*, p < 0.0001. (lower middle) qRT-PCR also showed a significant decrease of PD-L1 mRNA expression with
U0126. *, p < 0.05. Data are the mean of three or four independent experiments. (lower) One representative
immunoblot of phospho-ERK.
doi:10.1371/journal.pone.0166626.g002
RAS–MAPK Signal and PD-L1 in Human Lung Cancers
PLOS ONE | DOI:10.1371/journal.pone.0166626 November 15, 2016 8 / 18
Pretreatment with MEK inhibitor U0126 completely abrogated the PD-L1 mRNA increase,
suggesting the PMA dominantly activate MAPK signal. Furthermore, we subjected these cell
lines to ERK2 RNAi and found a significant decrease in PD-L1 expression at both protein and
mRNA levels, except for the protein expression of NCI-H441 (Fig 3B). Surface protein sup-
pression was weaker in the ERK2 RNAi (11–22%) than in the U0126 experiments (50–60%)
(Fig 2), which may be explained by the incomplete knockdown of ERK2 (Fig 3B), residual
ERK1 activity, and potentially the presence of signal cross-talk between other MAPKKs inhib-
ited by U0126 and cJUN, a transcription factor primarily driven by MAPK signaling. Collec-
tively, these results suggest that MAPK signaling contributes to ectopic PD-L1 expression in
KRAS-mutant lung cancer cell lines. The contribution of KRAS to downstream MAPK signal-
ing and PD-L1 expression was confirmed by KRAS RNAi experiments, in which two siRNAs
specific for KRAS mRNA led to the significant suppression of PD-L1 as well as ERK phosphor-
ylation, but not of the phosphorylation of AKT or STAT3 (Fig 3C and S4 Fig).
AP-1 activity downstream of MAPK signal controls PD-L1 expression
Next, we examined the activity of PD-L1 promoter/enhancer regions. PD-L1 promoter frag-
ment (−2403 to +153 from TSS) contains the binding sites for transcription factors except AP-
1. A candidate AP-1 binding site was found at chr9:5455433–5455446 according to GRCh37/
hg19 in the first intron of the PD-L1 gene by ChIP-seq data from UCSC Genome Browser (Fig
4A). The promoter fragment and a candidate enhancer fragment containing the AP-1 site
(+4785 to +5056 from TSS) were cloned to a pGL4.17 luciferase vector, and the PD-L1 pro-
moter alone (PDL-P) and the PD-L1 promoter plus a candidate AP-1 enhancer (PDL-P+E)
vectors were constructed (Fig 4B). Luciferase assays were conducted in the NCI-H1373 cell
line with or without U0126. Luciferase activity was significantly higher in PDL-P+E than in
PDL-P (p< 0.001), but this difference was not found with U0126 (Fig 4C), suggesting that
MAPK signaling regulates enhancer activity in the candidate AP-1 binding site. We performed
a ChIP assay to confirm the binding of an AP-1 component, cJUN, to this region and found
significant binding (Fig 4D), demonstrating the regulation of PD-L1 transcription under
MAPK signaling.
STAT3, but not PI3K, is partially involved in the control of PD-L1
expression
Next, we evaluated the contribution of signaling pathways other than MAPK signaling down-
stream of KRAS to ectopic PD-L1 expression. We subjected the three KRAS-mutant lung ade-
nocarcinoma cell lines to STAT3 RNAi, and PD-L1 expression decreased in two of them,
NCI-H1373 and NCI-H441, but not in NCI-H358 cells, at both protein and mRNA levels (Fig
5A and 5B). The degree of PD-L1 suppression with STAT3 RNAi was relatively weak (10–
32%) compared with that with U0126, and PD-L1 expression was not affected in one cell line,
indicating that the regulatory mechanism of PD-L1 by STAT3 signaling may not occur as
widely as MAPK signaling.
PI3K signaling, another downstream feature under KRAS, was also evaluated. LY294002, a
PI3K inhibitor, did not decrease PD-L1 expression in any of the three KRAS-mutant lung ade-
nocarcinoma cell lines (Fig 5C, upper). A time course experiment with LY294002 did not
show any decrease in PD-L1 levels from 24 h to 72 h after the treatment (data not shown).
Immunoblot (Fig 5C, lower) also showed similar PD-L1 protein levels, ruling out the possibil-
ity of an intracellular decrease in the level of PD-L1 protein. These results indicate the partial
contribution of STAT3, but not PI3K signaling, to ectopic PD-L1 expression in KRAS-mutant
human lung adenocarcinoma cell lines. Although our RNAi experiments did not show
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Fig 3. Regulation of PD-L1 by MAPK signaling is supported by PMA stimulation, ERK2 RNAi, and
KRAS RNAi. A, Three KRAS-mutant lung adenocarcinoma cell lines were serum-starved for 48 h, pre-
conditioned with DMSO or U0126 (20μM) for 1hr, then stimulated with 100 nM PMA for 15 min, and then
evaluated for phospho-ERK and PD-L1 mRNA levels. Immunoblot (upper) and qRT-PCR (lower) showed
increases in phospho-ERK and PD-L1 mRNA levels 15 min after PMA stimulation, respectively. *, p < 0.05.
Data are the mean of three independent experiments. B, Three KRAS-mutant lung adenocarcinoma cell lines
were transfected with two siRNAs (#1 and #2) specific for ERK2 or a control siRNA (siCtrl) at 100 nM. Forty-
eight hours after transfection, cells were harvested for analysis. (upper) Flow cytometric analysis showed the
significant suppression of surface PD-L1 levels, except in NCI-H441. (middle) qRT-PCR showed a significant
decrease in PD-L1 mRNA levels in all three cell lines. (lower) Immunoblotting indicated a significant decrease
in ERK2 protein levels with the two siRNAs. Data are the mean of three independent experiments. C, PD-L1
expression in NCI-H1373 cells was significantly suppressed with two siRNAs specific for KRAS (#1 and 2) at
both surface protein (upper left) and mRNA levels (lower left). Immunoblotting showed that the KRAS
knockdown was associated with the inhibition of ERK phosphorylation (right).
doi:10.1371/journal.pone.0166626.g003
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significant suppression of STAT3 signaling following KRAS RNAi (Fig 3C and S4 Fig), which
may be explained by the incomplete KRAS knockdown, distinct suppression of ERK phos-
phorylation was observed, indicating the dominant contribution of MAPK signaling to PD-L1
regulation.
PD-L1 expression is associated with other biological processes
We conducted a supervised cluster analysis between PD-L1-high and -low human lung cancer
cell lines using CCLE Analysis Tools: Differential Expression. PD-L1-high cell lines expressed
higher levels of mRNAs related to cell adhesion (TRIP6 and SH3KBP1), motility (VAV1 and
RAC2), cell proliferation (ANXA3 and IFI16), apoptosis (TNFAIP8 and SH3KBP1), cell signal-
ing (RAC2 and MST1R,), ubiquitination (FBXL13), a ligand for NKG2D (RAET1E), or metabo-
lism (CDA) than PD-L1-low cell lines (Fig 6A). The difference in the expression of some of
these genes between PD-L1-high and -low human lung cancer cell lines was confirmed by
qRT-PCR (Fig 6B and S2 Table). The levels of RAC2, CDA, MST1R, TRIP6, and RAET1Ewere
significantly higher in PD-L1-high than in PD-L1-low cell lines. However, because the mRNA
levels of MST1R, TRIP6, and RAET1E in PD-L1-high cell lines were lower than that in BEAS-
2B (RQ = 1), the functional significance of these differences is questionable. Next, we com-
pared the expression of RAC2 and CDA mRNAs between DMSO and U0126 treatments in the
three KRAS-mutant lung adenocarcinoma cell lines (Fig 6C). Significant suppression of the
Fig 4. Promoter assay experiments of PD-L1. A, Diagrammatic representation of the PD-L1 regulatory elements, including PD-L1 promoter
fragment and the predicted enhancer containing an AP-1 binding site. Fragments cloned into luciferase constructs are annotated below, with
positions relative to the PD-L1 TSS. B, Diagram of luciferase vectors. The empty pGL4.17 vector, the GL4.17 vector with the promoter cloned
upstream of the luciferase gene alone (PDL-P), the promoter with the enhancer cloned downstream of the luciferase gene (PDL-P+E). C, PD-L1
promoter- and enhancer-driven luciferase activity in NCI-H1373 with or without MEK inhibition. Firefly luciferase activity normalized by Renilla
luciferase activity significantly increased with PDL-P+E compared with that with PDL-P after DMSO treatment (left), while no significant difference
was found between PDL-P and PDL-P+E after U0126 treatment (right). Data are representative of three independent experiments with the same
results and shown as the mean of quadruplicate experiments. Error bars indicate SD. E, Binding of cJUN to the candidate PD-L1 enhancer region
following ChIP-coupled qPCR. Data are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0166626.g004
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Fig 5. STAT3 signal, but not PI3K signal, partially contributes to ectopic PD-L1 expression in human
lung cancer cell lines. A, STAT3 RNAi reduced PD-L1 expression at both protein (upper) and mRNA (lower)
levels in NCI-H1373 and NCI-H441 cells but not in NCI-H358 cells. The experimental conditions were similar
to those in Fig 3B. Data are the mean of three independent experiments. B, Immunoblot (upper) and
qRT-PCR (lower) of STAT3 showed the decreases in STAT3 protein and mRNA levels, respectively. One
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mRNA levels with U0126 compared with DMSO was found in RAC2 and CDA in all three cell
lines. Therefore, RAC2 and CDA as well as PD-L1 were considered to be regulated by the
MAPK signaling pathway. RAC2 is a small GTPase regulating diverse types of signal transduc-
tion related to the organization of actin filament and regulation of cell proliferation or lamelli-
podium assembly [20]. CDA is an enzyme involved in pyrimidine metabolism, catalyzing the
irreversible hydrolytic deamination of cytidine and deoxycytidine to uridine and deoxyuri-
dine, respectively [21]. It also inactivates gemcitabine, a chemotherapeutic agent against
NSCLCs.
GSEA showed that two pathways, actin cytoskeleton regulation by Rho GTPases and integ-
rin-mediated cell adhesion, significantly correlated to the PD-L1-high cell lines (Fig 6D). Both
supervised cluster analysis and GSEA indicated the possible relevance of enhanced cell motility
to increased PD-L1 expression, and a common pathway(s) regulating these molecules seems to
be, at least in part, MAPK signaling.
Discussion
The mechanisms of ectopic PD-L1 expression in human cancers have been studied in lung
cancers [10–13], melanomas [14,15], malignant lymphomas [16–18], myelomas [19], and glio-
mas [9]. Oncogenic driver mutations, such as mutated EGFR [10,11], EML4-ALK [13], or
NPM-ALK [16], with activated downstream signals, have been shown to contribute to ectopic
PD-L1 expression. These observations suggest that some constitutively activated signals are
targetable immune evasion signals, as previously indicated [6–8]. It has been reported that var-
ious signals including MAPK [13,14,17–19], STAT3 [16], or PI3K [9, 13, 14] are relevant to
PD-L1 expression; however, the contribution of each signal is inconsistent among different
cancers. In NSCLCs, EGFR mutation [10,11] and EML4-ALK fusion [13] have been shown to
be related to PD-L1 expression. Here we reported that KRAS mutation also contributes to
enhanced PD-L1 expression. Ota et al. showed that an MEK inhibitor (U0126) and a PI3K
inhibitor (LY294002), but not a STAT3 inhibitor (S3I–201), decrease PD-L1 expression in
EGFR-mutant and EML4-ALK-positive lung cancer cells, as determined by qRT-PCR and flow
cytometry [13]. However, direct evidence of the transcriptional regulation of PD-L1 by MAPK
signaling has not yet been obtained. We demonstrated that PD-L1 enhancer activity is driven
by AP-1 under MAPK signaling and the binding of cJUN to the candidate AP-1 site in a
human KRAS-mutant adenocarcinoma cell line. Contrary to the previous report mentioned
above, our analysis showed the partial contribution of STAT3, but not PI3K signaling, to
PD-L1 expression. The different mutational status may lead to different signaling pathways for
PD-L1 expression.
Our lung cancer panel of PD-L1-high cell lines included three squamous cell carcinomas
without any known oncogenic driver mutations and one large cell carcinoma with a KRAS
(Q61H) mutation (Table 1). However, the MEK inhibitor U0126 significantly reduced PD-L1
levels in these cell lines (S3 Fig), suggesting that MAPK signaling is involved in ectopic PD-L1
expression irrespective of any histological differences, even without any known oncogenic
driver mutations.
representative immunoblot and the mean of three independent qRT-PCR experiments are shown. C,
LY294002, a PI3K inhibitor, did not suppress PD-L1 protein expression. Three KRAS-mutant lung
adenocarcinoma cell lines were treated with DMSO or LY294002 (40 μM) for 24 h. PD-L1 protein levels did
not show any significant changes with LY294002 with regard to both the surface (upper) and total protein
(lower) levels. Data are the mean of three independent experiments.
doi:10.1371/journal.pone.0166626.g005
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Fig 6. Supervised cluster analysis and GSEA between PD-L1-high and -low human lung cancer cell lines suggested mRNA
upregulation of several molecules related to cell adhesion, motility, cell proliferation, cell signaling, and pathways related to actin
cytoskeleton regulation and integrin-mediated cell adhesion. A, Supervised cluster analysis of 10 PD-L1-high versus 10 PD-L1-low human
lung cancer cell lines. Depicted by the CCLE Analysis Tools: Differential Expression (http://www.broadinstitute.org/ccle/data/browseAnalyses). B,
qRT-PCR of 11 selected mRNAs in PD-L1-high and -low cell lines. The ΔΔCt method was used for the target mRNA, which was normalized by
endogenous β-actin mRNA and reference BEAS-2B cells. RQ data are the mean of 10 cell lines. C, RAC2 and CDA mRNA levels were compared
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Our data using KRAS-mutated lung cancer cell lines may suggest the translational impor-
tance of this mechanistic link in clinical lung cancer tissues. A correlation between PD-L1
expression and the status of KRAS mutation in larger sets of laser microdissected clinical lung
tumor cells should be warranted.
Ota et al. [13] and we could not identify the complete loss of PD-L1 expression with a MEK
inhibitor, suggesting that MAPK signaling only contributes to the enhancer activity of PD-L1,
which was supported by our luciferase assay results showing substantial transcriptional activity
in the promoter fragment (-2403 to +153 from TSS) without AP-1 sites (PDL-P, Fig 4C). This
promoter sequence includes potential binding sites for other transcription factors, such as
IRF-1 [22], NF-κB [23], STAT-3 [24], and HIF-1α [25]. Therefore, PD-L1 expression seems to
depend not only on MAPK signaling but also on other regulatory signals, for which further
analysis is warranted.
Two KRAS-mutant lung adenocarcinoma cell lines, SK-LU-1 and NCI-H23, did not express
PD-L1 at both mRNA and protein levels (Fig 1, S1 Table and S1 Fig). Akbay et al. reported
that the forced expression of mutant KRAS (G12V) in BEAS-2B does not induce PD-L1
expression [10], suggesting that the mutant KRAS is insufficient for PD-L1 expression. Skouli-
dis et al. recently reported three subsets (KL, KP, and KC subtypes) of KRAS-mutant lung ade-
nocarcinoma cell lines according to the co-occurring genetic events as determined by an
integrative analysis of genomic, transcriptomic, and proteomic data [26]. These subsets
showed biologically and therapeutically relevant differences, and KP tumors exhibited higher
levels of somatic mutations, immune checkpoint effector molecules including PD-L1, and
improved relapse-free survival. The inconsistency in PD-L1 expression among the KRAS-
mutant lung adenocarcinoma cell lines may reflect their heterogeneity.
We identified RAC2 and CDA as genes with significantly higher expression in PD-L1-high
lung cancer cell lines. The expression of these genes as well as PD-L1 was dependent on MAPK
signaling, suggesting that MAPK signaling constitutes a common pathway for an immune
checkpoint molecule, and other functional molecules regulating cell motility, proliferation, or
pyrimidine metabolism. GSEA identified that the pathways of the actin cytoskeleton regulation
by Rho GTPases and integrin-mediated cell adhesion are significantly related to PD-L1-high
lung cancer cell lines. These signatures may be related to the enhanced cellular motility or
invasive ability and are reminiscent of the findings in a previous report by Chen et al. describ-
ing the correlation between PD-L1 expression and epithelial—mesenchymal transition (EMT)
[12]. We also found the substantial expression of several chemokines (CXCL1, CXCL5,
CXCL8, and CX3CL1) related to cell migration, invasion, metastasis, or EMT [27–30], in
KRAS-mutant lung adenocarcinoma cell lines, which was also dependent on MAPK signaling
(unpublished data). Although the functional significance of these molecules requires further
investigation, we speculate that MAPK signaling regulates gene expression related to EMT and
immune evasion. Furthermore, we found CCL17 (TARC) expression was higher, while
CXCL3 expression was lower in PD-L1-high cell lines than in PD-L1-low cell lines, respec-
tively (S5 Fig). CCL17 is related to the recruitment of Th2 cells and regulatory T cells, and
CXCL3 can recruit neutrophils and fibroblasts. Functional significance of these chemokine
profiles needs further evaluation.
In summary, this study showed that PD-L1 expression is regulated by MAPK and partially
by STAT3 signaling in KRAS-mutant lung adenocarcinoma cell lines. We also demonstrated
between DMSO and U0126 treatments in the three KRAS-mutant lung adenocarcinoma cell lines. The target mRNAs were normalized with
endogenous β-actin mRNAs and DMSO-treated cells as a reference (ΔΔCt method). Data are the mean of three independent experiments. D,
GSEA showed significant results for pathways related to actin cytoskeleton regulation by Rho GTPases and to integrin-mediated cell adhesion.
doi:10.1371/journal.pone.0166626.g006
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the MAPK-dependent transcriptional activity of AP-1, as well as the binding of cJUN to AP-1,
in the PD-L1 gene. MAPK signaling also regulates PD-L1 in squamous and large-cell lung car-
cinoma cell lines. PD-L1 is correlated with the expression of other functional genes (RAC2 and
CDA) and to pathways related to the cytoskeleton and cell adhesion, suggesting possible impli-
cations for EMT.
Supporting Information
S1 Fig. Flow cytometric analysis of human lung cancer cell lines. A, Ten PD-L1-high cell
lines (RQ> 2.7 in Fig 1). B, Ten PD-L1-low cell lines (RQ< 1). Empty and shaded histograms
indicate isotype control and PD-L1, respectively. BEAS-2B, a normal human bronchial cell
line, is shown as a reference.
(PDF)
S2 Fig. Increase in micro-RNA expression with MEK inhibition. qRT-PCR (ΔΔCt method)
of KRAS-mutant lung adenocarcinoma cell lines showed inconsistent increases in the expres-
sion of miR-200a, miR-200b, and miR-200c with U0126 (20 μM, 24 h). Each miRNA level was
normalized by miR-16 (an internal control) and DMSO-treated cells (reference). Data are the
mean of three independent experiments.
(PDF)
S3 Fig. MEK inhibition significantly decreased the PD-L1 expression of EGFR-mutant
lung adeno-, squamous cell, or large cell carcinomas at both protein and mRNA levels.
(A) NCI-H1975, an adenocarcinoma cell line harboring EGFR mutation (L858R, T790M);
(B) EBC-1, a squamous cell carcinoma cell line; and (C) NCI-H460, a large cell carcinoma cell
line. Data are the mean of three independent experiments.
(PDF)
S4 Fig. KRASRNAi decreased PD-L1 expression in two KRAS-mutant lung adenocarci-
noma cell lines, NCI-H358 and NCI-H441. A, Surface protein (relative MFI) (upper) and
mRNA levels (RQ) (lower) of PD-L1. Data are the mean of three independent experiments. B,
Immunoblot shows KRAS knockdown and decreased ERK phosphorylation. One representa-
tive result of two or three independent experiments.
(PDF)
S5 Fig. Supervised cluster analysis of chemokine expression between PD-L1-high and -low
human lung cancer cell lines. CCL17 expression is higher, while CXCL3 expression is lower
in PD-L1-high than in PD-L1-low lung cancer cell lines.
(PDF)
S1 Table. PD-L1 RQ and MFI of human lung cancer cell lines.
(XLSX)
S2 Table. Primer sets for qRT-PCR.
(XLSX)
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